0.0250
+0.0050
+(25.00%)
At close: January 16 at 10:42:31 AM EST
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Rebecca Lynn Hudson C.A., CPA | Chief Financial Officer | 72k | -- | -- |
| Mr. Derek Lloyd Harry Ivany | Executive Chairman | -- | -- | 1984 |
| Mr. Steve Loutskou | President, CEO & Director | -- | -- | -- |
| Dr. Aylia Mohammadi B.Sc., M.Sc., Ph.D. | President & Chief Scientific Officer of Nova Mentis Biotech Corp. | 36k | -- | 1980 |
| Ms. Kelly Pladson | Corporate Secretary | -- | -- | 1983 |
Restart Life Sciences Corp.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Restart Life Sciences Corp. was incorporated in 2004 and is based in Vancouver, Canada.
Corporate Governance
Restart Life Sciences Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
April 7, 2025 at 8:00 PM UTC - April 11, 2025 at 8:00 PM UTC
Restart Life Sciences Corp. Earnings Date
Recent Events
Recent Events Information Not Available